South Korea · Delayed Price · Currency is KRW High Tech Pharm Statistics
Total Valuation
High Tech Pharm has a market cap or net worth of KRW 140.36 billion. The enterprise value is 133.41 billion.
| Market Cap | 140.36B |
| Enterprise Value | 133.41B |
Important Dates
The next estimated earnings date is Wednesday, November 12, 2025.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
High Tech Pharm has 10.63 million shares outstanding. The number of shares has increased by 50.28% in one year.
| Current Share Class | 10.63M |
| Shares Outstanding | 10.63M |
| Shares Change (YoY) | +50.28% |
| Shares Change (QoQ) | +0.38% |
| Owned by Insiders (%) | 5.54% |
| Owned by Institutions (%) | 0.32% |
| Float | 5.84M |
Valuation Ratios
The trailing PE ratio is 13.31.
| PE Ratio | 13.31 |
| Forward PE | n/a |
| PS Ratio | 1.88 |
| PB Ratio | 1.14 |
| P/TBV Ratio | 1.14 |
| P/FCF Ratio | 8.33 |
| P/OCF Ratio | 7.23 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.59, with an EV/FCF ratio of 7.91.
| EV / Earnings | 12.63 |
| EV / Sales | 1.79 |
| EV / EBITDA | 7.59 |
| EV / EBIT | 10.86 |
| EV / FCF | 7.91 |
Financial Position
The company has a current ratio of 3.67, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.67 |
| Quick Ratio | 1.90 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.44 |
| Debt / FCF | 0.46 |
| Interest Coverage | 23.50 |
Financial Efficiency
Return on equity (ROE) is 8.91% and return on invested capital (ROIC) is 5.87%.
| Return on Equity (ROE) | 8.91% |
| Return on Assets (ROA) | 5.39% |
| Return on Invested Capital (ROIC) | 5.87% |
| Return on Capital Employed (ROCE) | 9.92% |
| Revenue Per Employee | 1.15B |
| Profits Per Employee | 162.52M |
| Employee Count | 65 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 1.77 |
Taxes
In the past 12 months, High Tech Pharm has paid 2.46 billion in taxes.
| Income Tax | 2.46B |
| Effective Tax Rate | 18.88% |
Stock Price Statistics
The stock price has decreased by -5.80% in the last 52 weeks. The beta is 0.77, so High Tech Pharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | -5.80% |
| 50-Day Moving Average | 12,632.00 |
| 200-Day Moving Average | 13,591.30 |
| Relative Strength Index (RSI) | 60.93 |
| Average Volume (20 Days) | 43,437 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, High Tech Pharm had revenue of KRW 74.65 billion and earned 10.56 billion in profits. Earnings per share was 991.66.
| Revenue | 74.65B |
| Gross Profit | 16.11B |
| Operating Income | 12.29B |
| Pretax Income | 13.02B |
| Net Income | 10.56B |
| EBITDA | 17.58B |
| EBIT | 12.29B |
| Earnings Per Share (EPS) | 991.66 |
Balance Sheet
The company has 14.70 billion in cash and 7.76 billion in debt, giving a net cash position of 6.95 billion or 653.16 per share.
| Cash & Cash Equivalents | 14.70B |
| Total Debt | 7.76B |
| Net Cash | 6.95B |
| Net Cash Per Share | 653.16 |
| Equity (Book Value) | 123.20B |
| Book Value Per Share | 11,587.10 |
| Working Capital | 49.79B |
Cash Flow
In the last 12 months, operating cash flow was 19.42 billion and capital expenditures -2.56 billion, giving a free cash flow of 16.86 billion.
| Operating Cash Flow | 19.42B |
| Capital Expenditures | -2.56B |
| Free Cash Flow | 16.86B |
| FCF Per Share | 1,585.52 |
Margins
Gross margin is 21.59%, with operating and profit margins of 16.46% and 14.15%.
| Gross Margin | 21.59% |
| Operating Margin | 16.46% |
| Pretax Margin | 17.44% |
| Profit Margin | 14.15% |
| EBITDA Margin | 23.55% |
| EBIT Margin | 16.46% |
| FCF Margin | 22.58% |
Dividends & Yields
This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 0.75%.
| Dividend Per Share | 100.00 |
| Dividend Yield | 0.75% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 10.07% |
| Buyback Yield | -50.28% |
| Shareholder Yield | -49.56% |
| Earnings Yield | 7.53% |
| FCF Yield | 12.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 27, 2023. It was a forward split with a ratio of 1.5.
| Last Split Date | Dec 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
High Tech Pharm has an Altman Z-Score of 6.96 and a Piotroski F-Score of 5.
| Altman Z-Score | 6.96 |
| Piotroski F-Score | 5 |